MYOS vs. VBIV, TLPH, COCP, NERV, BNTC, ORGS, KPRX, HUGE, AYTU, and KALA
Should you be buying MYOS RENS Technology stock or one of its competitors? The main competitors of MYOS RENS Technology include VBI Vaccines (VBIV), Talphera (TLPH), Cocrystal Pharma (COCP), Minerva Neurosciences (NERV), Benitec Biopharma (BNTC), Orgenesis (ORGS), Kiora Pharmaceuticals (KPRX), FSD Pharma (HUGE), Aytu BioPharma (AYTU), and KALA BIO (KALA). These companies are all part of the "medical" sector.
MYOS RENS Technology (NASDAQ:MYOS) and VBI Vaccines (NASDAQ:VBIV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, community ranking, analyst recommendations, earnings, risk, profitability and media sentiment.
In the previous week, VBI Vaccines had 2 more articles in the media than MYOS RENS Technology. MarketBeat recorded 2 mentions for VBI Vaccines and 0 mentions for MYOS RENS Technology. MYOS RENS Technology's average media sentiment score of 0.00 beat VBI Vaccines' score of -0.32 indicating that MYOS RENS Technology is being referred to more favorably in the media.
5.0% of MYOS RENS Technology shares are owned by institutional investors. Comparatively, 12.3% of VBI Vaccines shares are owned by institutional investors. 45.3% of MYOS RENS Technology shares are owned by company insiders. Comparatively, 10.4% of VBI Vaccines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MYOS RENS Technology has higher earnings, but lower revenue than VBI Vaccines.
MYOS RENS Technology has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, VBI Vaccines has a beta of 1.93, meaning that its stock price is 93% more volatile than the S&P 500.
VBI Vaccines received 391 more outperform votes than MYOS RENS Technology when rated by MarketBeat users. Likewise, 74.96% of users gave VBI Vaccines an outperform vote while only 68.13% of users gave MYOS RENS Technology an outperform vote.
MYOS RENS Technology has a net margin of -277.82% compared to VBI Vaccines' net margin of -1,069.29%. MYOS RENS Technology's return on equity of -166.68% beat VBI Vaccines' return on equity.
Summary
VBI Vaccines beats MYOS RENS Technology on 8 of the 13 factors compared between the two stocks.
Get MYOS RENS Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for MYOS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MYOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MYOS RENS Technology Competitors List
Related Companies and Tools
